Long-term Documentation on the Use of Apremilast in Patients With Psoriatic Arthritis in Practice Conditions
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms LAPIS-PsA
- Sponsors Celgene Corporation
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2018 Planned End Date changed from 31 Aug 2018 to 30 Jun 2019.